Affinity Asset Advisors
TRAX icon

Affinity Asset Advisors’s First Tracks Biotherapeutics TRAX Stock Holding History

Affinity Asset Advisors’s Portfolio TRAX Stock Details TRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$73.7M Buy
2,080,000
+47,988
+2% +$1.87M 3% 6
2026
Q2 		$40.9M Buy
+2,032,012
New +$38M 1.85% 15

Other funds holding TRAX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Affinity Asset Advisors's TRAX Position: Q3 2026 in Review

Affinity Asset Advisors increased its First Tracks Biotherapeutics (TRAX) stake by 2.4% in Q3 2026, buying an estimated $1.87M and bringing the position to 2,080,000 shares worth $73.7M. The position accounts for 3% of the portfolio, ranked #6.

Affinity Asset Advisors first reported a position in TRAX in Q2 2026 and has held it in 2 quarters since. 118 funds tracked by Wall St. Rank hold TRAX as of Q3 2026.

  • Affinity Asset Advisors held 2,080,000 shares of First Tracks Biotherapeutics worth $73.7M as of Q3 2026.
  • Affinity Asset Advisors bought 47,988 First Tracks Biotherapeutics shares in Q3 2026, an estimated $1.87M.
  • First Tracks Biotherapeutics made up 3% of Affinity Asset Advisors's portfolio in Q3 2026, its #6 holding.
  • Affinity Asset Advisors first reported a position in First Tracks Biotherapeutics in Q2 2026 and has held it in 2 quarters since.
  • 118 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q3 2026.

Based on Affinity Asset Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.